Item 7.01 Regulation FD Disclosure.

On January 5, 2023, Landos Biopharma, Inc. (the "Company") issued a press release to announce a comprehensive update on its future development plans. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The Company also updated its corporate presentation on January 5, 2023 for use in meetings with investors, analysts and others. The presentation is available through the Company's website and a copy is attached as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibits 99.1 and 99.2) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits




Exhibit     Exhibit Description
Number
99.1          Press Release, dated January 5, 2023.
99.2          Corporate Presentation, dated January 5, 2023.
104         The cover page from Landos Biopharma, Inc.'s Form 8-K filed on January
            5, 2023, formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses